Neurological Biomarkers Market By Type (Genomic, Proteomic, Metabolomic, Others), By Application (Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease): Global Opportunity Analysis and Industry Forecast, 2021-2031

Neurological Biomarkers Market By Type (Genomic, Proteomic, Metabolomic, Others), By Application (Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease): Global Opportunity Analysis and Industry Forecast, 2021-2031

Neurological biomarkers are measurable indicators of biological state or condition of patients suffering from neurodegenerative diseases. Brain diseases require plenty of markers to reflect the metabolic impairment of different brain cells. The recent introduction of the metabolomic approach helps the study of neurological diseases based on profiling a multitude of biochemical components related to brain metabolism.

Major factors driving growth of the neurological biomarkers market include increase in geriatric population that are prone to neurological diseases, rise in head injuries, rise in prevalence of Alzheimer’s disease, Parkinson’s disease, and multiple Sclerosis. For instance, according to the latest WHO data published in 2020 Parkinson's disease deaths in Australia reached 2,036 or 1.49% of total deaths. The age adjusted Death Rate is 3.35 per 100,000 of population ranks Australia #131 in the world. According to WHO update 2022, globally, disability and death due to Parkinson’s disease are increasing faster than for any other neurological disorder.

For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.

Moreover, neurology is one of the disciplines where personalized medicine has been emerging as an important part of treatment methods for Alzheimer’s, Parkinson’s and Multiple Sclerosis. Neurological biomarkers find a varied scope in personalized medicine, which eventually spurs the demand for diagnosis by incorporating neurological biomarkers. Therefore, rise in the demand for personalized medicine boost the growth of neurological biomarkers market.

Furthermore, increase in demand for minimally invasive procedures propels the adoption of neurological biomarkers product. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the growth of the neurological biomarkers market. For instance, in June 2021, Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, announced a partnership with University of California, San Francisco (UCSF) and UC Berkeley to speed up the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS) such as Alzheimer’s, Parkinson’s, Huntington’s, Amyotrophic lateral sclerosis (ALS) and autism. UCSF and UC Berkeley had received up to $53 million from Genentech over the course of the 10-year collaboration.

However, the emerging ethical issues regarding early diagnosis of Alzheimer’s disease, Parkinson’s disease, and multiple Sclerosis is expected to impede the market growth. strict government regulations and high cost for neurological biomarkers products also restrain the market growth.

Furthermore, healthcare business is predicted to witness growth, owing increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer’s and Parkinson’s, increase in R&D investments in drug discovery & development, and rise in awareness regarding neurological biomarker. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The neurological biomarkers market is segmented on the basis of type, application, and region. On the basis of type, the market is classified into genomic, proteomic, metabolomic, and others. By application, the market is segregated into Alzheimer's disease, Parkinson's disease, and multiple sclerosis. 

Region wise, the market is analyzed across North America (the U.S., and Canada), Europe (Germany, France, the UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and Rest of LAMEA).

Major players profiled in the report are Biomérieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGAA, Myriad Genetics, Inc., Neurobio, Perkinelmer Inc., Quanterix, Shimadzu Corporation, Thermo Fisher Scientific, Inc.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the diabetic nephropathy market to identify the prevailing opportunities
This study presents the competitive landscape of the global market to predict the competitive environment across various regions
Comprehensive analysis of factors that drive and restrict the market growth is provided
Region & country wise analysis is provided to understand the market trends and dynamics

Key Market Segments

By Type

Genomic
Proteomic
Metabolomic
Others

By Application

Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis

By Region

North America
U.S.
Canada
Europe
Germany
France
UK
Rest Of Europe
Asia-Pacific
Japan
China
India
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
Rest Of LAMEA

Key Market Players

F. HOFFMANN-LA ROCHE LTD.
Bio-Rad Laboratories, Inc.
merck kgaa, darmstadt, germany
PERKINELMER INC.
shimadzu corporation
Thermo Fisher Scientific, Inc.
Quanterix
Neurobio
bioMérieux
MYRIAD RBM (MYRIAD GENETICS, INC.)

Please Note: It will take 7-10 business days to complete the report upon order confirmation.